Everest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Simply Wall St.

Aug 21

It's been a pretty great week for Everest Medicines Limited (HKG:1952) shareholders, with its shares surging 18% to HK$33.66 in the week since its latest half-yearly results. Revenues of CN¥1.1...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2661256976"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2661256976\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2661256976?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-21 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661256976","market":"hk","top_or_hot":-1,"title":"Everest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year","media":"Simply Wall St.","content":"<div>\n<p>It's been a pretty great week for Everest Medicines Limited (HKG:1952) shareholders, with its shares surging 18% to HK$33.66 in the week since its latest half-yearly results.        Revenues of CN¥1.1...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limited-hkg1952-interim-results-just-came\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Everest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEverest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-21 06:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limited-hkg1952-interim-results-just-came><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's been a pretty great week for Everest Medicines Limited (HKG:1952) shareholders, with its shares surging 18% to HK$33.66 in the week since its latest half-yearly results.        Revenues of CN¥1.1...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limited-hkg1952-interim-results-just-came\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VOTE","symbol_name":"TCW Transform 500 ETF","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limited-hkg1952-interim-results-just-came","article_id":"2661256976","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limited-hkg1952-interim-results-just-came","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2661256976","pubTimestamp":1787266310,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"It's been a pretty great week for Everest Medicines Limited ( HKG:1952 ) shareholders, with its shares surging 18% to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"VOTE":"TCW Transform 500 ETF","01952":"云顶新耀","GXDW":"Global X Dorsey Wright Thematic ETF","BK1161":"生物科技","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","BK1574":"生物医药B类股","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","RGLO":"Global Equity Active ETF","MDCO":"麦迪逊医药","VGFPF":"Vanguard Funds PLC","BK1583":"高瓴概念","PMDE":"PGIM S&P 500 Max Buffer ETF - December"},"translate_title":"珠穆朗玛峰药业有限公司 (HKG:1952) 中期业绩刚刚出炉：以下是分析师对今年的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DECU":0.69,"FEBU":0.69,"RGLO":0.69,"VOTE":0.69,"GXDW":0.69,"MDCO":1.5,"01952":1.5,"VGFPF":0.69,"PMDE":0.69,"JOYT":0.69},"content_text":"It's been a pretty great week for Everest Medicines Limited (HKG:1952) shareholders, with its shares surging 18% to HK$33.66 in the week since its latest half-yearly results.        Revenues of CN¥1.1b arrived in line with expectations, although statutory losses per share were CN¥0.02, just a small fraction of what broker models predicted.      Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company.  With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.SEHK:1952 Earnings and Revenue Growth August 20th 2026 Taking into account the latest results, the current consensus from Everest Medicines' five analysts is for revenues of CN¥3.35b in 2026. This would reflect a huge 39% increase on its revenue over the past 12 months.      Everest Medicines is also expected to turn profitable, with statutory earnings of CN¥1.91 per share.       Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥3.30b and earnings per share (EPS) of CN¥0.63 in 2026.        Although the revenue estimates have not really changed, we can see there's been a massive increase in earnings per share expectations, suggesting that the analysts have become more bullish after the latest result.     Check out our latest analysis for Everest Medicines   There's been no major changes to the consensus price target of HK$40.67, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation.        Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation.  There are some variant perceptions on Everest Medicines, with the most bullish analyst valuing it at HK$69.45 and the most bearish at HK$25.73 per share.   With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business.  With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.      Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates.     It's clear from the latest estimates that Everest Medicines' rate of growth is expected to accelerate meaningfully, with the forecast 93% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 77% p.a. over the past five years.    Compare this with other companies in the same industry, which are forecast to grow their revenue 22% annually.  Factoring in the forecast acceleration in revenue, it's pretty clear that Everest Medicines is expected to grow much faster than its industry.     AdvertisementThe Bottom Line  The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Everest Medicines following these results.        Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry.       The consensus price target held steady at HK$40.67, with the latest estimates not enough to have an impact on their price targets.   With that in mind, we wouldn't be too quick to come to a conclusion on Everest Medicines. Long-term earnings power is much more important than next year's profits.   We have estimates - from multiple Everest Medicines analysts - going out to 2028, and you can see them free on our platform here.  You should always think about risks though. Case in point, we've spotted   1 warning sign for Everest Medicines  you should be aware of.   Valuation is complex, but we're here to simplify it.Discover if Everest Medicines might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}